Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/12 | undisclosed | Strategic |
In-Q-Tel | undisclosed |
| 03/06/12 | $2,000,000 | |||
| 11/15/12 | $18,500,000 | Series C |
ARCH Venture Partners bioMerieux Flagship Ventures In-Q-Tel | undisclosed |
| 03/23/16 | $46,000,000 | Series D |
ARCH Venture Partners Cormorant Asset Management Dr. David Walt Hercules Technology Growth Capital Trinitas Capital Tufts University | undisclosed |
| 08/03/17 | $8,500,000 |
T. Rowe Price | undisclosed |
